Albany Molecular Research (AMRI) Receives $4M Milestone Payment From Bristol-Myers
More News related to AMRI
- AMRI Initiates Phase I Study on ALB109564
- AMRI Initiates Phase I Study of Proprietary Oncology Drug Candidate
- AMRI CEO Adopts Rule 10B5-1 Stock Trading Plan
- Unusual 11 Mid-Day Movers 8/6: VRNM, CBOU, SCA, AMRI Higher; INAP, ENTR, MFLX, ABCO Lower
- Pre-Open Movers 8/6: Freddie Mac (FRE) Sinks On Results, Isolagen (ILE) Surges On Drug Results
More News related to BMY
- Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ESC Highlights
- Analyst Reports for Bristol-Myers Squibb Company, Merck & Co. Inc., Idearc Inc., and Northwest Airlines Corporation
- Bristol-Myers (BMY) and Pfizer (PFE) Provide Update on Apixaban Clinical Development Program - Primary Endpoint Not Met
- Bristol-Myers Squibb and Pfizer Provide Update on Apixaban Clinical Development Program
- Pre-Open Movers 8/20: Novatel (NVTL) Sinks On Results/Guidance; Suntech (STP) Higher
Albany Molecular Research (NASDAQ: AMRI) said it will receive a $4 million milestone payment from Bristol-Myers Squibb Company (NYSE: BMY) as a result of Bristol-Myers Squibb's submission of a Clinical Trial Application (CTA) to the Health Products and Food Branch (HPFB), Health Canada for approval to initiate Phase I studies on an AMRI compound exclusively licensed to Bristol-Myers Squibb. Upon approval of the CTA by Health Canada, Bristol-Myers Squibb may begin Phase I testing in Canada.
Related Categories
FDAStocks Mentioned
-0.11Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
